Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors

Fumihiko Furuya, Changxue Lu, Celine J. Guigon, Sheue Yann Cheng

Research output: Contribution to journalArticle

Abstract

Thyroid hormone (T3) is critical in growth, development, differentiation, and maintenance of metabolic homeostasis. Recent studies suggest that thyroid hormone receptors (TRs) not only mediate the biological activities of T3 via nucleus-initiated transcription, but also could act via nongenomic pathways. The striking phenotype of thyroid cancer exhibited by a knockin mutant mouse that harbors a dominant negative TRβ mutant (TRβPV/PV mouse) allows the elucidation of novel oncogenic activity of a TRβ mutant (PV) via extra-nuclear actions. PV physically interacts with the regulatory p85α subunit of phosphatidylinositol 3-kinase (PI3K) to activate the downstream AKT-mammalian target of rapamycin (mTOR) and p70S6K and PI3K-integrin-linked kinase-matrix metalloproteinase-2 signaling pathways. The PV-mediated PI3K activation results in increased cell proliferation, motility, migration, and metastasis. Remarkably, a nuclear receptor corepressor (NCoR) was found to regulate the PV-activated PI3K signaling by competing with PV for binding to the C-terminal SH2 domain of p85α. Over-expression of NCoR in thyroid tumor cells of TRβPV/PV mice reduces AKT-mTOR-p70S6K signaling. Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells leads to over-activated PI3K-AKT signaling to increase cell proliferation and motility. Furthermore, NCoR protein levels are significantly lower in thyroid tumor cells than in wild type thyrocytes, allowing more effective binding of PV to p85α to activate PI3K signaling, thereby contributing to tumor progression. Thus, PV, an apo-TRβ, could act via direct protein-protein interaction to mediate critical oncogenic actions. These studies also uncovered a novel extra-nuclear role of NCoR in modulating the nongenomic actions of a mutated TRβ in controlling thyroid carcinogenesis.

Original languageEnglish (US)
Pages (from-to)628-634
Number of pages7
JournalSteroids
Volume74
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Thyroid Hormone Receptors
Co-Repressor Proteins
Chemical activation
Tumors
70-kDa Ribosomal Protein S6 Kinases
Thyroid Gland
Cells
Cell proliferation
Sirolimus
Cell Movement
Neoplasms
Cell Proliferation
src Homology Domains
Matrix Metalloproteinase 2
Triiodothyronine
Transcription
Ports and harbors
Bioactivity
Growth and Development

Keywords

  • Mouse model
  • Nongenomic actions
  • Nuclear receptor corepressor
  • Phosphatidylinositol 3-kinase
  • Thyroid cancer
  • Thyroid hormone receptors

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Molecular Biology
  • Organic Chemistry
  • Pharmacology

Cite this

Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. / Furuya, Fumihiko; Lu, Changxue; Guigon, Celine J.; Cheng, Sheue Yann.

In: Steroids, Vol. 74, No. 7, 07.2009, p. 628-634.

Research output: Contribution to journalArticle

Furuya, Fumihiko ; Lu, Changxue ; Guigon, Celine J. ; Cheng, Sheue Yann. / Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. In: Steroids. 2009 ; Vol. 74, No. 7. pp. 628-634.
@article{26a37792ae3e443ab228888b30c870ef,
title = "Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors",
abstract = "Thyroid hormone (T3) is critical in growth, development, differentiation, and maintenance of metabolic homeostasis. Recent studies suggest that thyroid hormone receptors (TRs) not only mediate the biological activities of T3 via nucleus-initiated transcription, but also could act via nongenomic pathways. The striking phenotype of thyroid cancer exhibited by a knockin mutant mouse that harbors a dominant negative TRβ mutant (TRβPV/PV mouse) allows the elucidation of novel oncogenic activity of a TRβ mutant (PV) via extra-nuclear actions. PV physically interacts with the regulatory p85α subunit of phosphatidylinositol 3-kinase (PI3K) to activate the downstream AKT-mammalian target of rapamycin (mTOR) and p70S6K and PI3K-integrin-linked kinase-matrix metalloproteinase-2 signaling pathways. The PV-mediated PI3K activation results in increased cell proliferation, motility, migration, and metastasis. Remarkably, a nuclear receptor corepressor (NCoR) was found to regulate the PV-activated PI3K signaling by competing with PV for binding to the C-terminal SH2 domain of p85α. Over-expression of NCoR in thyroid tumor cells of TRβPV/PV mice reduces AKT-mTOR-p70S6K signaling. Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells leads to over-activated PI3K-AKT signaling to increase cell proliferation and motility. Furthermore, NCoR protein levels are significantly lower in thyroid tumor cells than in wild type thyrocytes, allowing more effective binding of PV to p85α to activate PI3K signaling, thereby contributing to tumor progression. Thus, PV, an apo-TRβ, could act via direct protein-protein interaction to mediate critical oncogenic actions. These studies also uncovered a novel extra-nuclear role of NCoR in modulating the nongenomic actions of a mutated TRβ in controlling thyroid carcinogenesis.",
keywords = "Mouse model, Nongenomic actions, Nuclear receptor corepressor, Phosphatidylinositol 3-kinase, Thyroid cancer, Thyroid hormone receptors",
author = "Fumihiko Furuya and Changxue Lu and Guigon, {Celine J.} and Cheng, {Sheue Yann}",
year = "2009",
month = "7",
doi = "10.1016/j.steroids.2008.10.009",
language = "English (US)",
volume = "74",
pages = "628--634",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors

AU - Furuya, Fumihiko

AU - Lu, Changxue

AU - Guigon, Celine J.

AU - Cheng, Sheue Yann

PY - 2009/7

Y1 - 2009/7

N2 - Thyroid hormone (T3) is critical in growth, development, differentiation, and maintenance of metabolic homeostasis. Recent studies suggest that thyroid hormone receptors (TRs) not only mediate the biological activities of T3 via nucleus-initiated transcription, but also could act via nongenomic pathways. The striking phenotype of thyroid cancer exhibited by a knockin mutant mouse that harbors a dominant negative TRβ mutant (TRβPV/PV mouse) allows the elucidation of novel oncogenic activity of a TRβ mutant (PV) via extra-nuclear actions. PV physically interacts with the regulatory p85α subunit of phosphatidylinositol 3-kinase (PI3K) to activate the downstream AKT-mammalian target of rapamycin (mTOR) and p70S6K and PI3K-integrin-linked kinase-matrix metalloproteinase-2 signaling pathways. The PV-mediated PI3K activation results in increased cell proliferation, motility, migration, and metastasis. Remarkably, a nuclear receptor corepressor (NCoR) was found to regulate the PV-activated PI3K signaling by competing with PV for binding to the C-terminal SH2 domain of p85α. Over-expression of NCoR in thyroid tumor cells of TRβPV/PV mice reduces AKT-mTOR-p70S6K signaling. Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells leads to over-activated PI3K-AKT signaling to increase cell proliferation and motility. Furthermore, NCoR protein levels are significantly lower in thyroid tumor cells than in wild type thyrocytes, allowing more effective binding of PV to p85α to activate PI3K signaling, thereby contributing to tumor progression. Thus, PV, an apo-TRβ, could act via direct protein-protein interaction to mediate critical oncogenic actions. These studies also uncovered a novel extra-nuclear role of NCoR in modulating the nongenomic actions of a mutated TRβ in controlling thyroid carcinogenesis.

AB - Thyroid hormone (T3) is critical in growth, development, differentiation, and maintenance of metabolic homeostasis. Recent studies suggest that thyroid hormone receptors (TRs) not only mediate the biological activities of T3 via nucleus-initiated transcription, but also could act via nongenomic pathways. The striking phenotype of thyroid cancer exhibited by a knockin mutant mouse that harbors a dominant negative TRβ mutant (TRβPV/PV mouse) allows the elucidation of novel oncogenic activity of a TRβ mutant (PV) via extra-nuclear actions. PV physically interacts with the regulatory p85α subunit of phosphatidylinositol 3-kinase (PI3K) to activate the downstream AKT-mammalian target of rapamycin (mTOR) and p70S6K and PI3K-integrin-linked kinase-matrix metalloproteinase-2 signaling pathways. The PV-mediated PI3K activation results in increased cell proliferation, motility, migration, and metastasis. Remarkably, a nuclear receptor corepressor (NCoR) was found to regulate the PV-activated PI3K signaling by competing with PV for binding to the C-terminal SH2 domain of p85α. Over-expression of NCoR in thyroid tumor cells of TRβPV/PV mice reduces AKT-mTOR-p70S6K signaling. Conversely, lowering cellular NCoR by siRNA knockdown in tumor cells leads to over-activated PI3K-AKT signaling to increase cell proliferation and motility. Furthermore, NCoR protein levels are significantly lower in thyroid tumor cells than in wild type thyrocytes, allowing more effective binding of PV to p85α to activate PI3K signaling, thereby contributing to tumor progression. Thus, PV, an apo-TRβ, could act via direct protein-protein interaction to mediate critical oncogenic actions. These studies also uncovered a novel extra-nuclear role of NCoR in modulating the nongenomic actions of a mutated TRβ in controlling thyroid carcinogenesis.

KW - Mouse model

KW - Nongenomic actions

KW - Nuclear receptor corepressor

KW - Phosphatidylinositol 3-kinase

KW - Thyroid cancer

KW - Thyroid hormone receptors

UR - http://www.scopus.com/inward/record.url?scp=63649143022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63649143022&partnerID=8YFLogxK

U2 - 10.1016/j.steroids.2008.10.009

DO - 10.1016/j.steroids.2008.10.009

M3 - Article

VL - 74

SP - 628

EP - 634

JO - Steroids

JF - Steroids

SN - 0039-128X

IS - 7

ER -